These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 7569830)

  • 1. [Prevention of postmenopausal osteoporosis: how effective is transdermal hormone substitution? (Continuous estradiol plus sequential oral norethisterone acetate)].
    Gass R; Neff M
    Schweiz Med Wochenschr; 1995 Aug; 125(34):1583-91. PubMed ID: 7569830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Osteoporosis prevention initiated with peripheral quantitative computerized tomography. Thin-layer and multi-layer technique].
    Gass R; Neff M
    Praxis (Bern 1994); 1995 May; 84(18):521-5. PubMed ID: 7754270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
    Rozenberg S; Ylikorkala O; Arrenbrecht S
    Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transdermal sequential and continuous hormone replacement regimens with estradiol and norethisterone acetate in postmenopausal women: effects on the endometrium.
    Johannisson E; Holinka CF; Arrenbrecht S
    Int J Fertil Womens Med; 1997; 42 Suppl 2():388-98. PubMed ID: 9397386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17beta-estradiol and dydrogesterone.
    Lippuner K; Haenggi W; Birkhaeuser MH; Casez JP; Jaeger P
    J Bone Miner Res; 1997 May; 12(5):806-12. PubMed ID: 9144347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal estroprogestins versus transdermal estrogen plus oral dihydrogesterone replacement in menopause.
    Marchesoni D; Dal Pozzo M; Dal Magro L; Paternoster DM; Ferroni E; Maggino T; Romagnolo C; Mozzanega B
    J Endocrinol Invest; 1996 May; 19(5):268-72. PubMed ID: 8796334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
    Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
    Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The metabolic and bone density effects of continuous combined 17-beta estradiol and noresthisterone acetate treatments in Thai postmenopausal women: a double-blind placebo-controlled trial.
    Bunyavejchevin S; Limpaphayom KK
    J Med Assoc Thai; 2001 Jan; 84(1):45-53. PubMed ID: 11281499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy.
    Popp AW; Bodmer C; Senn C; Fuchs G; Kraenzlin ME; Wyss H; Birkhaeuser MH; Lippuner K
    Maturitas; 2006 Jan; 53(2):191-200. PubMed ID: 16368472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study.
    Alexandersen P; Riis BJ; Christiansen C
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3013-20. PubMed ID: 10487657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
    Davis SR; Goldstat R; Newman A; Berry K; Burger HG; Meredith I; Koch K
    Climacteric; 2002 Dec; 5(4):341-50. PubMed ID: 12626213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The avoidance of early postmenopausal bone substance losses by transdermal estrogen substitution].
    Ringe JD; Meiss F
    Dtsch Med Wochenschr; 1993 May; 118(21):769-74. PubMed ID: 8504712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipids and clotting factors during low dose transdermal estradiol/norethisterone use.
    Brynhildsen J; Hammar M
    Maturitas; 2005 Apr; 50(4):344-52. PubMed ID: 15780536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of transdermal and oral hormone replacement therapies on monocyte chemoattractant protein-1 levels: a randomized clinical trial.
    Taşçı T; Şükür YE; Özmen B; Atabekoğlu CS; Cengiz SD; Koçbulut E; Berker B; Sönmezer M
    Eur J Obstet Gynecol Reprod Biol; 2014 May; 176():50-4. PubMed ID: 24655552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects on serum lipid profiles of continuous 17beta-estradiol, intermittent norgestimate regimens versus continuous combined 17beta-estradiol/norethisterone acetate hormone replacement therapy.
    Ylikorkala O; Lim P; Caubel P
    Clin Ther; 2000 May; 22(5):622-36. PubMed ID: 10868559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of effects of sequential transdermal administration versus oral administration of estradiol plus norethisterone acetate on serum NO levels in postmenopausal women.
    Kurtay G; Ozmen B; Erguder I
    Maturitas; 2006 Jan; 53(1):32-8. PubMed ID: 16325022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of postmenopausal hormone replacement therapy on body fat composition.
    Yüksel H; Odabasi AR; Demircan S; Köseoğlu K; Kizilkaya K; Onur E
    Gynecol Endocrinol; 2007 Feb; 23(2):99-104. PubMed ID: 17454160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women.
    Castelo-Branco C; Vicente JJ; Figueras F; Sanjuan A; Martínez de Osaba MJ; Casals E; Pons F; Balasch J; Vanrell JA
    Maturitas; 2000 Feb; 34(2):161-8. PubMed ID: 10714911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects.
    Greenwald MW; Gluck OS; Lang E; Rakov V
    Menopause; 2005; 12(6):741-8. PubMed ID: 16278618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of low-dose transdermal E2/NETA on the reduction of postmenopausal bone loss in women.
    Rubinacci A; Peruzzi E; Modena AB; Zanardi E; Andrei B; De Leo V; Pansini FS; Quebe-Fehling E; de Palacios PI
    Menopause; 2003; 10(3):241-9. PubMed ID: 12792297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.